Replies to post #406878 on Anavex Life Sciences Corp (AVXL)

[Investor2014]

This is why I am very intrigued to see the KEM analysis that includes before and after poo samples from the: OLE Study for Patients With Parkinson's Disease With Dementia Enrolled in Study ANAVEX2-73-PDD-001.

Other Outcome Measures:
Microbiota [ Time Frame: 48 weeks ]
Change from baseline to End of Treatment as measured by microbiota

This follows on from these findings: Anavex Life Sciences Presents ANAVEX®2-73 (blarcamesine) Data at 12th Clinical Trials on Alzheimer’s Disease (CTAD) 2019 Conference

I believe that similarly microbiota samples are also part of the P2b/3 OLE study.